Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-191532
Filing Date
2026-04-29
Accepted
2026-04-29 16:08:12
Documents
17
Period of Report
2026-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A prld-20260429.htm   iXBRL DEF 14A 981654
2 GRAPHIC img124090035_0.gif GRAPHIC 7345
3 GRAPHIC img124090035_1.gif GRAPHIC 178041
4 GRAPHIC img124090035_2.gif GRAPHIC 172250
5 GRAPHIC img124090035_3.jpg GRAPHIC 341021
6 GRAPHIC img124090035_4.jpg GRAPHIC 392348
  Complete submission text file 0001193125-26-191532.txt   4876903

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20260429.xsd EX-101.SCH 15022
20 EXTRACTED XBRL INSTANCE DOCUMENT prld-20260429_htm.xml XML 355847
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39527 | Film No.: 26915998
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)